Nickan Research Institute Journal of Renal Injury Prevention 2345-2781 11 4 2022 12 01 Ameliorative impact of sodium–glucose cotransporter-2 inhibitors in diabetic kidney disease; a mini- review to current evidence e31947 e31947 10.34172/jrip.2022.31947 EN Dorsa Jahangiri https://orcid.org/0000-0003-1918-3583 Atousa Najmaldin https://orcid.org/0000-0002-8434-1341 Lakkakula VKS Bhaskar https://orcid.org/0000-0003-2977-6454 Journal Article 10.34172/jrip.2022.31947 2021 08 10 2021 08 29 The sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a new class of antidiabetic agents. SGLT2i are able to inhibit SGLT2 transporter in renal tissue, increasing glycosuria and reducing blood sugar. These drugs act by inhibiting the SGLT2 in renal proximal epithelial tubular cells. SGLT2i are found to have beneficial effect on chronic renal failure caused by diabetic nephropathy.